Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

UAC unveiled an unmanned transportation system

8/12/24 UNAC

Board of Directors of Ashinskiy metallurgical works recommended dividends

8/12/24 AMEZ

Yaroslavnefteorgsintez reported for 6 months of 2024 by RAS

8/12/24 JNOS

Tatneft launches serial production of tires in Kazakhstan

8/12/24 TATN

Mosgorlombard's revenue for January-July increased 4 times

8/12/24 MGKL

Bank Saint-Petersburg reported for 6 months of 2024 by RAS

8/9/24 BSPB

Rosbank reported for 6 months of 2024 by RAS

8/9/24 ROSB

NovaBev Group reported for 6 months of 2024 by RAS

8/9/24 BELU

VK Clips service has surpassed TikTok in popularity for the first time

8/9/24 VKCO

PhosAgro increases fertilizer shipments to Africa by 74%

8/9/24 PHOR